PFE Jun 2023 50.000 call
| Previous close | 0.0100 |
| Open | 0.0100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 50.00 |
| Expiry date | 2023-06-16 |
| Day's range | 0.0100 - 0.0100 |
| Contract range | N/A |
| Volume | |
| Open interest | 34.56k |
Yahoo Finance VideoAbortion access debate hits the business world
Following the striking down of Roe v. Wade, activist investors are pushing companies to disclose the impact new abortion rights laws could have their businesses. Yahoo Finance legal reporter Alexis Kennan breaks down what investors want to know.
ZacksPfizer (PFE) Gains But Lags Market: What You Should Know
Pfizer (PFE) closed at $39.09 in the latest trading session, marking a +0.51% move from the prior day.
ZacksMerck (MRK) Sues US Government to Halt Drug Price Negotiations
Merck (MRK) files a lawsuit against claiming that the federal government is violating the Constitution by forcing drugmakers to negotiate prices at below market rates.
ZacksGSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults
The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.
Motley Fool2 Unstoppable Stocks to Buy Before the Bull Market
In a full-blown bull market, many businesses could see their valuations skyrocket, particularly those that are focused on growth. Palantir Technologies has been a hot stock lately, soaring more than 130% since the start of 2023. Artificial intelligence (AI) and the potential growth opportunities that it can open up for Palantir are what have been driving a lot of the recent bullishness for the business.
Business WirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK, June 06, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.
Motley FoolCould Pfizer Have an Ozempic Killer on the Way?
It wasn't because so many patients were newly diagnosed with type 2 diabetes. Instead, Ozempic gained widespread popularity for helping people lose weight. A sibling product, Wegovy, a higher-dose version of the active ingredient in Ozempic that is actually approved for weight loss, has flown off pharmacies' shelves as well.
Motley FoolLooking for Passive Income at a Decent Price? Buy These 2 Stocks
Many investors would love to buy passive income stocks with a high dividend yield, a sustainable level of earnings coverage of the dividend, and a cheap valuation. For instance, Zoloft, Xanax, Lyrica, Viagra, and Lipitor are just a few of the older household-name drug brands that Viatris (NASDAQ: VTRS) counts in its portfolio of generic medicines, and while none are new medicines, they're each indispensable to this day. Viatris' forward dividend yield is presently above 5.2%, which is on the high side compared to the market's average yield of around 1.6%.
Motley Fool3 Dividend Stocks You Can Buy Without Any Hesitation
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
Motley FoolWhy Shares of BioNTech Rose Friday
Shares of BioNTech (NASDAQ: BNTX) were up as by much as 5.3% on Friday before closing the session up 3.85% after the biotech company announced positive news regarding a clinical trial for its non-small cell lung cancer therapy candidate. The company focuses on immunotherapies to treat cancer, infectious diseases, and other diseases. BioNTech's shares have been sliding because sales of Comirnaty, the COVID-19 vaccine it developed with Pfizer, are falling.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
Motley FoolWhy Biohaven Stock Caught Fire This Week
Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.
ZacksPfizer (PFE) Down 1.1% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ZacksBiohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Business WirePhase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
NEW YORK, June 01, 2023--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel investigational antibiotic combination aztreonam-avibactam (ATM-AVI) in treating serious bacterial infections due to Gram-negative bacteria, including metallo-β-lactamase (MBL)-producing multidrug-resistant pathogens for which there are limited or no treatme
Motley FoolHave $2,000? 2 Remarkable Growth Stocks to Buy Right Now
Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.
ZacksPfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.
Business WireU.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
NEW YORK, May 31, 2023--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective.
Motley FoolWhy Pfizer Stock Is Perking Up Today
Shares of pharma titan Pfizer (NYSE: PFE) were up by 2.24% on moderate volume as of 2:29 p.m. ET Wednesday afternoon. Earlier Wednesday, The Wall Street Journal published a column questioning whether investors have turned too bearish on COVID-19 vaccine-makers like Pfizer. Pfizer's shares have fallen by as much as 30% this year in response to the anticipated drop in sales for its COVID-19 vaccine Comirnaty and antiviral treatment Paxlovid.
ZacksPfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study
Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.
Motley FoolDoes Pfizer Have a Weight-Loss Pill That's Better Than Ozempic?
A highly lucrative weight-loss market could be the growth opportunity Pfizer needs to make the stock a better buy.
Motley Fool2 Ultra-Safe Dividend Stocks to Load Up On Right Now
Which top-shelf dividend stocks are worth buying right now? Allstate (NYSE: ALL) and Pfizer (NYSE: PFE) are two near-locks to produce healthy levels of capital appreciation over the next five to 10 years. Allstate's 2023 Q1 earnings report isn't exactly a confidence-inspiring read.
ZacksValneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
ZacksPfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Business WirePfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl
